<DOC>
	<DOCNO>NCT01517308</DOCNO>
	<brief_summary>Aim present study evaluate cohort patient genotype 2/3 chronic hepatitis C , relapsers previous PEG-IFN + ribavirin therapy ( alpha-2a alpha-2b ) efficacy PEG-IFNÎ±-2a + ribavirin administer 24 48 week . It evaluate whether 48 week therapy may achieve good result compare standard duration ( 24 week ) .</brief_summary>
	<brief_title>24 VS 48-WEEK TREATMENT WITH PEG-IFN ALPHA-2A IN PATIENTS WITH GENOTYPE 2/3 CHRONIC HEPATITIS C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Written inform consent Age 18 year Compensated liver disease follow preenrollment hematological parameter : Hemoglobin 13 g/dl male 12 g/dl female ; White blood cell count 3,000/mmc ; Platelet count 100,000 /mmc Antinuclear antibody ( ANA ) less 1:160 AntiLiverKidney antibody ( LKM1 ) : negative alpha1 fetoprotein level less 50 ng/ml 3 month enrollment liver Ultrasound negative focal malignant lesion . HBsAg : negative Clinical histological diagnosis chronic hepatitis C HCVRNA : positive Relapse ( endoftreatment HCVRNA negativity positivization within 6 month therapy withdrawal ) atleast one previous treatment PEGIFN ( alpha2a alpha2b ) + ribavirin last least 80 % 24 planned week least 80 % total plan dose PEGIFN ribavirin administer . Normal value total direct bilirubin ( exception indirect bilirubin due extrahepatic factor Gilbert syndrome ; case level less 3 mg/dL ) . Normal value albumin creatinin Normal fasting glycemia , case glycemic value 115mg/dL 140 mg/dl ( value confirm one determination ) patient affect diabetes mellitus , glycated hemoglobin &lt; 8,5 % . Normal Thyroid Stimulating Hormone ( TSH ) level . Subjects pharmacological treatment maintain normal TSH level enrol fulfill criterion . In case history diabetes hypertension specialist examination require rule contraindication therapy . Adoption contraceptive measure Age less 18 year Women pregnancy breastfeed Previous treatment PEGIFN alpha2a alpha2b + ribavirin 6 month Participation clinical trial within 30 day enrollment protocol Subjects solid organ transplantation ( exception cornea hair transplantation ) Subject willing counseling abstain alcohol use Suspected hypersensitivity PEGInterferon alpha2a ribavirin Any cause liver disease different chronic hepatitis C base anamnesis patient histological evidence include limited : HBV coinfection Alpha1 antitrypsin deficiency Wilson disease Autoimmune hepatitis Alcoholic liver disease Hemoglobinopathy include limited thalassemia major . Advanced liver disease diagnose history presence ascites , esophageal variceal bleed hepatic encephalopathy Psychiatric condition : depression medical history severe psychiatric alteration major psychosis , suicidal idea , suicidal attempt , depression require hospitalization electroconvulsive therapy , prolonged work leave significant impairment everyday activity exclude . Subjects history slight depression might consider enrollment study pretreatment psychiatric evaluation indicate subject stable possible follow mental status study . Central nervous system trauma convulsive status require treatment . Cardiovascular disease ( e.g . angina , congestive heart disease , myocardial infarction , major arrhythmia ) . Decompensated diabetes mellitus Clinical gout Chronic pulmonary disease Immunemediated disease ( e.g . chronic inflammatory bowel disease , idiopathic thrombocytopenic purpura , Systemic lupus erythematosus , autoimmune hemolytic anemia , scleroderma , severe psoriasis ) Abuse substances alcohol ( 80 g/die ) , i.v . inhalator drug . Subjects history drug abuse enrol abstinent least 2 year . Subjects clinically relevant retinal lesion Any condition investigator opinion could reason non suitability patient interfere his/her participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>HCV</keyword>
	<keyword>Hepatitis</keyword>
	<keyword>Genotype 2 3</keyword>
	<keyword>Pegylated Interferon</keyword>
	<keyword>Duration</keyword>
</DOC>